Основная статистика
| CIK | 1070698 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Raptor Pharmaceutical Corp.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| February 21, 2017 |
RPTP / Raptor Pharmaceutical Corp. / Credit Suisse Trust Ltd Passive Investment Page 1 of 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 4) Under the Securities Exchange Act of 1934 Horizon Pharmaceutical LLC (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 75382F106 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 14, 2017 |
RPTP / Raptor Pharmaceutical Corp. / SCOPIA CAPITAL MANAGEMENT LP - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2017 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them to Schedule 13G (including additional amendments thereto) with respect to the ordinary shares, nominal value $0.0001 per share, of Horizon Pharma Public Limited Company. This Joint Filing Agreement |
|
| January 13, 2017 |
RPTP / Raptor Pharmaceutical Corp. / Credit Suisse Trust Ltd Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 3) Under the Securities Exchange Act of 1934 Raptor Pharmaceutical Corporation (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 75382F106 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| November 4, 2016 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 000-25571 (Commission File Number) HORIZON PHARMACEUTICAL LLC (Exact name of registrant as s |
|
| October 31, 2016 |
CERTIFICATE OF FORMATION HORIZON PHARMACEUTICAL LLC EX-3.1 Exhibit 3.1 CERTIFICATE OF FORMATION OF HORIZON PHARMACEUTICAL LLC TO THE SECRETARY OF STATE OF THE STATE OF DELAWARE: The undersigned, an authorized natural person, for the purpose of forming a limited liability company, under the provisions and subject to the requirements of the State of Delaware (particularly Chapter 18, Title 6 of the Delaware Code, as amended, and referred to as the ?D |
|
| October 31, 2016 |
EX-3.2 3 d265444dex32.htm EX-3.2 Exhibit 3.2 STATE OF DELAWARE CERTIFICATE OF CONVERSION FROM A CORPORATION TO A LIMITED LIABILITY COMPANY PURSUANT TO SECTION 266 OF THE DELAWARE GENERAL CORPORATION LAW AND SECTION 18-214 OF THE DELAWARE LIMITED LIABILITY COMPANY ACT RAPTOR PHARMACEUTICAL CORP., a Delaware corporation (the “Company”), does hereby certify to the following facts relating to the conv |
|
| October 31, 2016 |
8-K 1 d265444d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2016 HORIZON PHARMACEUTICAL LLC (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction |
|
| October 25, 2016 |
Raptor Pharmaceutical FORM S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
Raptor Pharmaceutical FORM S-8 POS Form S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
Raptor Pharmaceutical FORM S-8 POS Form S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
Raptor Pharmaceutical FORM S-8 POS Form S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
Raptor Pharmaceutical FORM S-8 POS Form S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
Raptor Pharmaceutical FORM S-8 POS Form S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
Raptor Pharmaceutical FORM S-8 POS Form S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
Raptor Pharmaceutical FORM S-8 POS Form S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
Raptor Pharmaceutical FORM S-8 POS Form S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
Raptor Pharmaceutical FORM S-8 POS Form S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
Raptor Pharmaceutical FORM S-8 POS Form S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
Raptor Pharmaceutical FORM S-8 POS Form S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
Raptor Pharmaceutical FORM S-8 POS Form S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
Raptor Pharmaceutical FORM S-8 POS S-8 POS 1 d276065ds8pos.htm FORM S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. 333-204834 Registration No. 333-202577 Registration No. 333-198186 Registration No. 333-190806 Registration No. 333-173719 Registration No. 333-166813 Registration No. 333-163124 Registration No. 333-151859 Registration No. 333-141738 Registration No. 333-138368 Regist |
|
| October 25, 2016 |
POS AM As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
POS AM As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
POS AM As filed with the Securities and Exchange Commission on October 25, 2016 Registration No. |
|
| October 25, 2016 |
AMENDED AND RESTATED RAPTOR PHARMACEUTICAL CORP. (A DELAWARE CORPORATION) ARTICLE I EX-3.2 3 d275237dex32.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF RAPTOR PHARMACEUTICAL CORP. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be 2711 Centerville Road, Suite 400, City of Wilmington, County of New Castle, 19808 or in such other location as the Board of Directors may from time |
|
| October 25, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2016 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporatio |
|
| October 25, 2016 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION RAPTOR PHARMACEUTICAL CORP. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RAPTOR PHARMACEUTICAL CORP. I. The name of this corporation is RAPTOR PHARMACEUTICAL CORP. II. The registered office of the corporation in the State of Delaware shall be 2711 Centerville Road, Suite 400, City of Wilmington, County of New Castle, Zip Code 19808, and the name of the registered agent of the corporation in the Sta |
|
| October 25, 2016 |
Raptor Pharmaceutical SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RAPTOR PHARMACEUTICAL CORP. (Name of Subject Company) RAPTOR PHARMACEUTICAL CORP. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securitie |
|
| October 25, 2016 |
Raptor Pharmaceutical SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) Raptor Pharmaceutical Corp. (Name of Subject Company) Misneach Corporation (Name of Offeror) An Indirect Wholly-Owned Subsidiary of Horizon Pharma Public Limited Company (Name of Offerors) (N |
|
| October 25, 2016 |
EX-99.(a)(5)(ii) Exhibit (a)(5)(ii) Horizon Pharma plc Completes Acquisition of Raptor Pharmaceutical Corp. - Adds Two Rare Disease Medicines and Further Diversifies Company Revenue - - Raises Full-Year 2016 Net Sales Guidance and Confirms Full-Year 2016 Adjusted EBITDA Guidance - DUBLIN, IRELAND ? October 25, 2016 ? Horizon Pharma plc (NASDAQ: HZNP) a biopharmaceutical company focused on improvin |
|
| October 20, 2016 |
Raptor Pharmaceutical SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) Raptor Pharmaceutical Corp. (Name of Subject Company) Misneach Corporation (Name of Offeror) An Indirect Wholly-Owned Subsidiary of Horizon Pharma Public Limited Company (Name of Offerors) (Names of Fi |
|
| October 19, 2016 |
8-K 1 d273787d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2016 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdi |
|
| October 17, 2016 |
Raptor Pharmaceutical SCHEDULE 14D9/A (AMENDMENT NO. 3) SC 14D9/A 1 d255677dsc14d9a.htm SCHEDULE 14D9/A (AMENDMENT NO. 3) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RAPTOR PHARMACEUTICAL CORP. (Name of Subject Company) RAPTOR PHARMACEUTICAL CORP. (Name of Person Filing Statement) Common Stock, |
|
| October 14, 2016 |
Raptor Pharmaceutical SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) Raptor Pharmaceutical Corp. (Name of Subject Company) Misneach Corporation (Name of Offeror) An Indirect Wholly-Owned Subsidiary of Horizon Pharma Public Limited Company (Name of Offerors) (N |
|
| October 11, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2016 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation |
|
| October 11, 2016 |
RAPTOR PHARMACEUTICAL CORP. 5 Hamilton Landing, Suite 160 Novato, CA 94949 EX-10.1 Exhibit 10.1 Execution Version RAPTOR PHARMACEUTICAL CORP. 5 Hamilton Landing, Suite 160 Novato, CA 94949 October 5, 2016 HealthCare Royalty Partners II, L.P. HCRP Overflow Fund, L.P. MOLAG Healthcare Royalty, LLC 300 Atlantic Street, Suite 600 Stamford, CT 06901 Attention: Clarke B. Futch Email: [email protected] Note Redemption Agreement (this ?Agreement?) Ladies and Gentlemen: |
|
| October 6, 2016 |
Raptor Pharmaceutical SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RAPTOR PHARMACEUTICAL CORP. (Name of Subject Company) RAPTOR PHARMACEUTICAL CORP. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securitie |
|
| October 6, 2016 |
Raptor Pharmaceutical SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) Raptor Pharmaceutical Corp. (Name of Subject Company) Misneach Corporation (Name of Offeror) An Indirect Wholly-Owned Subsidiary of Horizon Pharma Public Limited Company (Name of Offerors) (Names of Fi |
|
| October 5, 2016 |
Raptor Pharmaceutical SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RAPTOR PHARMACEUTICAL CORP. (Name of Subject Company) RAPTOR PHARMACEUTICAL CORP. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securitie |
|
| October 5, 2016 |
EX-99.(A)(18) 2 d254370dex99a18.htm EX-99.(A)(18) Exhibit (a)(18) Frequently Asked Questions for Raptor employees (the “Employee FAQ”). The Employee FAQ was first used or made available on October 5, 2016. On September 26, 2016, Misneach Corporation, a Delaware corporation (“Merger Sub”) and an indirect wholly owned subsidiary of Horizon Pharma plc, a public limited company organized under the law |
|
| October 5, 2016 |
Raptor Pharmaceutical SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) Raptor Pharmaceutical Corp. (Name of Subject Company) Misneach Corporation (Name of Offeror) An Indirect Wholly Owned Subsidiary of Horizon Pharma Public Limited Company (Name of Offerors) (N |
|
| September 26, 2016 |
SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 26, 2016 |
Raptor Pharmaceutical Corp. 7 Hamilton Landing, Suite 100 Novato, CA 94949 EX-99.(a)(17) Exhibit (a)(17) Raptor Pharmaceutical Corp. 7 Hamilton Landing, Suite 100 Novato, CA 94949 September 26, 2016 Dear Stockholder: I am pleased to inform you that, on September 12, 2016, Raptor Pharmaceutical Corp. (Raptor) entered into a definitive Agreement and Plan of Merger (the Merger Agreement) with Horizon Pharma plc (Parent) and Misneach Corporation, an indirect wholly own |
|
| September 26, 2016 |
BANK OF AMERICA, N.A One Bryant Park New York, New York 10036 EX-(b)(i) Exhibit (b)(i) EXECUTION VERSION BANK OF AMERICA, N.A One Bryant Park New York, New York 10036 JPMORGAN CHASE BANK, N.A. 383 Madison Avenue New York, New York 10179 JEFFERIES FINANCE LLC 520 Madison Avenue New York, New York 10022 CITIGROUP GLOBAL MARKETS INC. 390 Greenwich Street New York, New York 10013 COWEN AND COMPANY, LLC COWEN STRUCTURED HOLDINGS, INC. 599 Lexington Avenue New Yor |
|
| September 26, 2016 |
EX-99.A.1.IV 5 d257266dex99a1iv.htm EX-(A)(1)(IV) Exhibit (a)(1)(iv) Offer To Purchase For Cash All Outstanding Shares of Common Stock of RAPTOR PHARMACEUTICAL CORP. at $9.00 Net per Share Pursuant to the Offer to Purchase dated September 26, 2016 by MISNEACH CORPORATION, an indirect wholly owned subsidiary of HORIZON PHARMA PUBLIC LIMITED COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT MID |
|
| September 26, 2016 |
EX-99.A.1.I 2 d257266dex99a1i.htm EX-(A)(1)(I) Table of Contents Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Raptor Pharmaceutical Corp., at $9.00 NET PER SHARE by Misneach Corporation an indirect wholly owned subsidiary of Horizon Pharma Public Limited Company THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT MIDNIGHT (NEW YORK TIME), AT THE END OF THE DAY |
|
| September 26, 2016 |
EX-(a)(1)(iii) Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY For Tender of All Outstanding Shares of Common Stock of RAPTOR PHARMACEUTICAL CORP. |
|
| September 26, 2016 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Raptor Pharmaceutical Corp. (Name of Subject Company) Misneach Corporation (Name of Offeror) An Indirect Wholly Owned Subsidiary of Horizon Pharma Public Limited Company (Name of Offerors) (Names of Filing Perso |
|
| September 26, 2016 |
EX-(a)(1)(vi) Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| September 26, 2016 |
CONFIDENTIALITY AGREEMENT June 6, 2016 Exhibit (d)(3) CONFIDENTIALITY AGREEMENT June 6, 2016 Horizon Pharma plc Connaught House, 1st Floor 1 Burlington Road Dublin 4 D04 C5Y6 Ireland Attention: Timothy P. |
|
| September 26, 2016 |
EX-(a)(1)(ii) Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of RAPTOR PHARMACEUTICAL CORP. |
|
| September 26, 2016 |
EX-(a)(1)(v) Exhibit (a)(1)(v) Offer To Purchase For Cash All Outstanding Shares of Common Stock of RAPTOR PHARMACEUTICAL CORP. |
|
| September 20, 2016 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RAPTOR PHARMACEUTICAL CORP. (Name of Subject Company) RAPTOR PHARMACEUTICAL CORP. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 75382F106 (CUSIP |
|
| September 20, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RAPTOR PHARMACEUTICAL CORP. (Name of Subject Company) RAPTOR PHARMACEUTICAL CORP. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 75382F106 (CUSIP Number o |
|
| September 13, 2016 |
Raptor Pharmaceutical FORM 8-K FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2016 Horizon Pharma Public Limited Company (Exact name of registrant as specified in its charter) Ireland 001-35238 Not Applicable (State or other jurisdiction |
|
| September 13, 2016 |
BANK OF AMERICA, N.A One Bryant Park New York, New York 10036 EX-99.1 Exhibit 99.1 EXECUTION VERSION BANK OF AMERICA, N.A One Bryant Park New York, New York 10036 JPMORGAN CHASE BANK, N.A. 383 Madison Avenue New York, New York 10179 JEFFERIES FINANCE LLC 520 Madison Avenue New York, NY 10022 COWEN AND COMPANY, LLC COWEN STRUCTURED HOLDINGS, INC. 599 Lexington Avenue New York, New York 10022 CONFIDENTIAL September 12, 2016 Horizon Pharma, Inc. c/o Horizon Pha |
|
| September 12, 2016 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RAPTOR PHARMACEUTICAL CORP. (Name of Subject Company) RAPTOR PHARMACEUTICAL CORP. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 75382F106 (CUSIP |
|
| September 12, 2016 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RAPTOR PHARMACEUTICAL CORP. (Name of Subject Company) RAPTOR PHARMACEUTICAL CORP. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 75 |
|
| September 12, 2016 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RAPTOR PHARMACEUTICAL CORP. (Name of Subject Company) RAPTOR PHARMACEUTICAL CORP. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 75382F106 (CUSIP |
|
| September 12, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RAPTOR PHARMACEUTICAL CORP. (Name of Subject Company) RAPTOR PHARMACEUTICAL CORP. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 75382F106 (CUSIP Number o |
|
| September 12, 2016 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RAPTOR PHARMACEUTICAL CORP. (Name of Subject Company) RAPTOR PHARMACEUTICAL CORP. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 75382F106 (CUSIP |
|
| September 12, 2016 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RAPTOR PHARMACEUTICAL CORP. (Name of Subject Company) RAPTOR PHARMACEUTICAL CORP. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 75382F106 (CUSIP |
|
| September 12, 2016 |
Exhibit 10.1 Exhibit 10.1 TENDER AND SUPPORT AGREEMENT THIS TENDER AND SUPPORT AGREEMENT (this ?Agreement?) is entered into as of September 12, 2016, by and among Horizon Pharma plc, a public limited company organized under the laws of Ireland (?Parent?), Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent (?Merger Sub?), and (?Stockholder?). RECITALS A. |
|
| September 12, 2016 |
Exhibit 3.1 Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF RAPTOR PHARMACEUTICAL CORP. TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS? MEETINGS 1 Section 4. Place Of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 3 Section 7. Notice Of Meeti |
|
| September 12, 2016 |
Exhibit 99.1 Exhibit 99.1 Horizon Pharma plc to Acquire Raptor Pharmaceutical Corp. as Further Step in Building Leading Rare Disease Business - Transaction valued at $9.00 per share in cash with fully diluted equity value of approximately $800 million - - Transaction is expected to be accretive to adjusted EBITDA in 2017 - - Conference call today at 8 a.m. ET to discuss transaction - DUBLIN, IRELA |
|
| September 12, 2016 |
Exhibit 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG HORIZON PHARMA PLC, MISNEACH CORPORATION AND RAPTOR PHARMACEUTICAL CORP. DATED AS OF SEPTEMBER 12, 2016 Table of Contents Page ARTICLE I THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 ARTICLE II THE MERGER 6 2.1 The Merger 6 2.2 The Effective Time 6 2.3 The Closing 6 2.4 Effect of the Merger 6 2.5 Certificate of Incorporation and |
|
| September 12, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2016 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) |
|
| September 12, 2016 |
EX-99.2 Horizon Pharma plc Announced Acquisition of Raptor Pharmaceutical Corp. Further Strengthens Horizon Pharma?s Focus on Rare Diseases September 12, 2016 Exhibit 99.2 Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements related to the anticipated consummation of the acquisition of Raptor Pharmaceutical Corp. (Raptor) and t |
|
| September 12, 2016 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG HORIZON PHARMA PLC, MISNEACH CORPORATION AND RAPTOR PHARMACEUTICAL CORP. DATED AS OF SEPTEMBER 12, 2016 Table of Contents Page ARTICLE I THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 ARTICLE II THE MERGER 6 2.1 The Merger 6 2.2 The Effective Time 6 2.3 The Closing 6 2.4 Effect of the Merger 6 2.5 Certificate of Incorporation and Byla |
|
| September 12, 2016 |
EX-99.3 5 d248693dex993.htm EX-99.3 Exhibit 99.3 Horizon Pharma plc to Acquire Raptor Pharmaceutical Corp. as Further Step in Building Leading Rare Disease Business - Transaction valued at $9.00 per share in cash with fully diluted equity value of approximately $800 million - - Transaction is expected to be accretive to adjusted EBITDA in 2017 - - Conference call today at 8 a.m. ET to discuss tran |
|
| September 12, 2016 |
EX-99.1 Exhibit 99.1 TENDER AND SUPPORT AGREEMENT THIS TENDER AND SUPPORT AGREEMENT (this Agreement) is entered into as of September 12, 2016, by and among Horizon Pharma plc, a public limited company organized under the laws of Ireland (Parent), Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent (Merger Sub), and (Stockholder). RECITALS A. Stock |
|
| September 12, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2016 Horizon Pharma Public Limited Company (Exact name of registrant as specified in its charter) Ireland 001-35238 Not Applicable (State or other jurisdiction of in |
|
| August 4, 2016 |
Raptor Pharmaceutical 10-Q (Quarterly Report) 10-Q 1 rptp-10q20160630.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-25571 RAPTOR PHARMACEUTICAL |
|
| August 4, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition rptp-8k20160804.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2016 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of inc |
|
| August 4, 2016 |
rptp-ex99114.htm Exhibit 99.1 Raptor Pharmaceutical Corp. Reports Second Quarter 2016 Financial Results Quarterly Revenue Increased 37.3% Year-Over-Year, to $32.0 Million Raptor Raises 2016 Global Net Revenue Guidance to $125-$135 Million Company to Host Conference Call and Webcast Today at 4:30 p.m. EDT/1:30 p.m. PDT NOVATO, Calif., August 4, 2016 - Raptor Pharmaceutical Corp. (NASDAQ: RPTP), a b |
|
| July 7, 2016 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2016 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Commissio |
|
| May 27, 2016 |
rptp-8k20160527.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2016 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incor |
|
| May 13, 2016 |
rptp-8k20160509.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2016 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorp |
|
| May 5, 2016 |
rptp-ex99139.htm Exhibit 99.1 Raptor Pharmaceutical Corp. Reports First Quarter 2016 Financial Results PROCYSBI? Global Net Revenue Increased 34% Year-Over-Year, to $27.5 Million 2016 Non-GAAP Operating Expense Guidance Lowered to $125 ? $135 Million Full-Year 2016 Revenue Guidance Maintained at $115 ? $125 Million NOVATO, Calif., May 5, 2016 - Raptor Pharmaceutical Corp. (NASDAQ: RPTP) (?Raptor? |
|
| May 5, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 rptp-8k20160505.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2016 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction |
|
| May 5, 2016 |
Raptor Pharmaceutical 10-Q (Quarterly Report) rptp-10q20160331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-25571 RAPTOR PHARMACEUTICAL CORP. (Exac |
|
| April 29, 2016 |
Raptor Pharmaceutical 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 to Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-255 |
|
| March 15, 2016 |
Raptor Pharmaceutical 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2016 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Com |
|
| March 15, 2016 |
CORRESP U.S. Securities and Exchange Commission March 15, 2016 Page 1 March 15, 2016 VIA EDGAR Suzanne Hayes Office of Healthcare and Insurance Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Raptor Pharmaceutical Corp. Post-Effective Amendment No. 2 to Form S-3 Filed February 26, 2016 File No. 333-203095 Raptor Pharmaceutical Corp. |
|
| March 15, 2016 |
CORRESP U.S. Securities and Exchange Commission March 15, 2016 Page 1 March 15, 2016 VIA EDGAR Suzanne Hayes Office of Healthcare and Insurance Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Raptor Pharmaceutical Corp. Post-Effective Amendment No. 2 to Form S-3 Filed February 26, 2016 File No. 333-207370 Raptor Pharmaceutical Corp. |
|
| February 26, 2016 |
Table of Contents As filed with the Securities and Exchange Commission on February 26, 2016 Registration No. |
|
| February 26, 2016 |
Table of Contents As filed with the Securities and Exchange Commission on February 26, 2016 Registration No. |
|
| February 26, 2016 |
Raptor Pharmaceutical 10-K (Annual Report) 10-K 1 rptp-10k20151231.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-2 |
|
| February 26, 2016 |
POSASR Table of Contents As filed with the Securities and Exchange Commission on February 26, 2016 Registration No. |
|
| February 26, 2016 |
Table of Contents As filed with the Securities and Exchange Commission on February 26, 2016 Registration No. |
|
| February 26, 2016 |
Exhibit 21.1 LIST OF SUBSIDIARIES NAME OF SUBSIDIARY JURISDICTION OF INCORPORATION Raptor Pharmaceuticals Inc. (formerly known as Raptor Therapeutics Inc.), wholly-owned subsidiary of Registrant Delaware, United States Raptor European Products, LLC, wholly-owned subsidiary of Raptor Pharmaceuticals Inc. Delaware, United States, business office in Grand Cayman RPTP European Holdings C.V., wholly-ow |
|
| February 26, 2016 |
RAPTOR PHARMACEUTICAL CORP. 2010 stock Incentive PLAN 2016 RESTRICTED SHARE UNIT AWARD AGREEMENT EX-10.29 2 rptp-ex1029648.htm EX-10.29 Exhibit 10.29 RAPTOR PHARMACEUTICAL CORP. 2010 stock Incentive PLAN 2016 RESTRICTED SHARE UNIT AWARD AGREEMENT Raptor Pharmaceutical Corp., a Delaware corporation, (the “Company”), pursuant to its 2010 Stock Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”), an award of restricted share uni |
|
| February 25, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2016 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Comm |
|
| February 25, 2016 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Raptor Pharmaceutical Corp. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Corporate Update 2015 Global Net Revenue for PROCYSBI® of $94.2 Million Reported 2016 Global Net Revenue Guidance of $115 to $125 Million 2016 Anticipated PROCYSBI Growth of 25%-30% Year-Over Year Company to Host Conference Call and Webcast Today a |
|
| February 16, 2016 |
RPTP / Raptor Pharmaceutical Corp. / Ivanishvili Bidzina Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 2) Under the Securities Exchange Act of 1934 Raptor Pharmaceutical Corporation (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 75382F106 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 16, 2016 |
RPTP / Raptor Pharmaceutical Corp. / HCRP OVERFLOW FUND, L.P./SERIES B - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1 )* Under the Securities Exchange Act of 1934 RAPTOR PHARMACEUTICAL CORP. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 75382F106 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 16, 2016 |
EX-99.A CUSIP No. 75382F106 EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other reporting persons on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, par value $0.001 per share of Rapto |
|
| February 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* raptor pharmaceutical corp. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 75382F106 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 9, 2016 |
8-K 1 d136917d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2016 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction |
|
| February 9, 2016 |
RAPTOR PHARMACEUTICAL CORP. FORM OF CHANGE IN CONTROL SEVERANCE AGREEMENT EX-10.1 Exhibit 10.1 RAPTOR PHARMACEUTICAL CORP. FORM OF CHANGE IN CONTROL SEVERANCE AGREEMENT This Change in Control Severance Agreement (the ?Agreement?) is made and entered into by and between [ ] (?Executive?) and Raptor Pharmaceutical Corp. (the ?Company?), effective as of the latest date set forth below by the signatures of the parties hereto (the ?Effective Date?). R E C I T A L S A. The Bo |
|
| February 5, 2016 |
RPTP / Raptor Pharmaceutical Corp. / Hyperion Trading Segregated Portfolio Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* raptor pharmaceutical corp. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 75382F106 (CUSIP Number) September 28, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 28, 2016 |
RPTP / Raptor Pharmaceutical Corp. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 10, 2015 |
EX-99.1 Exhibit 99.1 Raptor Plans to Advance RP103 in a Registration Study in Huntington?s Disease Based on Favorable Treatment Effects at 36 Months in CYST-HD Trial Conference Call and Webcast Today at 8:00 a.m. EST/5:00 a.m. PST NOVATO, Calif., December 10, 2015 ? Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced 36-month efficacy results from a Phase 2/3 clinical trial evaluating RP103 |
|
| December 10, 2015 |
Raptor Pharmaceutical 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) ( |
|
| November 5, 2015 |
Exhibit 99.1 Raptor Pharmaceutical Corp. Reports Third Quarter 2015 Financial Results and Provides Corporate Update Record PROCYSBI ? Product Sales of $25.8 Million Raptor Raises 2015 PROCYSBI Revenue Guidance to $90-$95 Million Company to Host Conference Call and Webcast Today at 4:30 p.m. EST NOVATO, Calif., November 5, 2015 - Raptor Pharmaceutical Corp. (NASDAQ: RPTP), a biopharmaceutical compa |
|
| November 5, 2015 |
10-Q 1 form10q.htm RAPTOR PHARMACEUTICAL CORP. 10-Q 9-30-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number |
|
| November 5, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Commi |
|
| November 5, 2015 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of June 19, 2015, by and between Ashley Gould (“Executive”) and Raptor Pharmaceutical Corp. (the “Company”). Whereas, the Company desires to employ Executive as its SVP, General Counsel and Corporate Compliance effective as of July 15,2015 (the “Effective Date”), and Executive desir |
|
| October 9, 2015 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on October 9, 2015 Registration No. |
|
| October 5, 2015 |
EX-99.1 Exhibit 99.1 Raptor Pharmaceutical Completes Acquisition of Quinsair? Strengthens core position in treatment of rare diseases and provides additional opportunities for growth NOVATO, Calif., October 5, 2015 ? Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced that it has completed the acquisition of Quinsair? (levofloxacin inhalation solution) from Tripex Pharmaceuticals. Quinsair |
|
| October 5, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation |
|
| October 5, 2015 |
EX-2.1 Exhibit 2.1 AMENDED AND RESTATED ASSET PURCHASE AGREEMENT among: RAPTOR PHARMACEUTICALS INC., a Delaware corporation; RAPTOR PHARMACEUTICAL CORP., a Delaware corporation; and TRIPEX PHARMACEUTICALS, LLC, a Delaware limited liability company Dated as of October 2, 2015 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission |
|
| September 14, 2015 |
Raptor Pharmaceutical FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporat |
|
| September 14, 2015 |
EX-99.1 Exhibit 99.1 Raptor Pharmaceutical Provides Topline Results from Phase 2b CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis NOVATO, Calif., September 14, 2015 Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced topline results from the Phase 2b CyNCh study, which did not meet its primary endpoint of improving nonalcoholic steatohepatitis (NASH) in children. Th |
|
| September 9, 2015 |
EX-99.1 Exhibit 99.1 RISK FACTORS The risk factors indicated below, which were previously set forth in Part II, Item 1A, ?Risk Factors? of our Quarterly Report on Form 10-Q for the period ended June 30, 2015, have been revised to reflect, among other things, our entry into an asset purchase agreement with Tripex Pharmaceuticals, LLC (?Tripex?) in August 2015 to acquire various assets and rights re |
|
| September 9, 2015 |
Raptor Pharmaceutical FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporati |
|
| September 8, 2015 |
RAPTOR PHARMACEUTICAL CORP. SALES AGREEMENT EX-1.1 Exhibit 1.1 RAPTOR PHARMACEUTICAL CORP. $75,000,000 SALES AGREEMENT September 4, 2015 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Raptor Pharmaceutical Corp., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, fro |
|
| September 8, 2015 |
Filed Pursuant to Rule 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| September 8, 2015 |
Raptor Pharmaceutical FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporati |
|
| September 8, 2015 |
Exhibit 10.2 COMMERCIAL SUPPLY AGREEMENT This COMMERCIAL SUPPLY AGREEMENT (?Agreement?), dated as of August 20, 2015 (?Effective Date?), is made between PARI PHARMA GMBH, a German corporation, with a principal place of business at Moosstrasse 3, D-82319 Starnberg, Germany (?PARI?), and RAPTOR PHARMACEUTICALS, INC., a Delaware corporation, with a place of business at 7 Hamilton Landing, Suite 100, |
|
| September 8, 2015 |
EXECUTION VERSION AMENDMENT NO. 1 TO THE DEVELOPMENT AND LICENSE AGREEMENT EX-10.4 Exhibit 10.4 EXECUTION VERSION AMENDMENT NO. 1 TO THE DEVELOPMENT AND LICENSE AGREEMENT This Amendment No. 1 to the Development and License Agreement (this “Amendment No. 1”) is effective as of , 2015 by and between PARI PHARMA GMBH, a German corporation, with a principal place of business at Moosstrasse 3, D-82319 Starnberg, Germany (“PARI”), and RAPTOR PHARMACEUTICALS, INC., a Delaware c |
|
| September 8, 2015 |
Exhibit 10.3 EXECUTION VERSION LETTER AGREEMENT This Letter Agreement (the ?Agreement?) dated as of August 20, 2015, is made by and between PARI PHARMA GMBH, a company organized under the laws of Germany (?PARI?), and RAPTOR PHARMACEUTICALS, INC., a Delaware corporation (?RAPTOR?). RECITALS A. PARI GmbH, an affiliate of PARI, and MPEX Pharmaceuticals, Inc. (?MPEX?) entered into a Development and L |
|
| September 8, 2015 |
DEVELOPMENT AND LICENSE AGREEMENT EX-10.1 Exhibit 10.1 DEVELOPMENT AND LICENSE AGREEMENT This Development and License Agreement (this “Agreement”) effective as of 11th day of February, 2006 (“Effective Date”), is between PARI GmbH, a German corporation with a principal place of business at Moosstrasse 3, D-82319 Starnberg, Germany (“PARI”) and Mpex Pharmaceuticals, Inc., a Delaware corporation having a principal place of business |
|
| September 8, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation |
|
| September 8, 2015 |
EX-2.1 Exhibit 2.1 ASSET PURCHASE AGREEMENT between: RAPTOR PHARMACEUTICAL CORP., a Delaware corporation; and TRIPEX PHARMACEUTICALS, LLC, a Delaware limited liability company Dated as of August 20, 2015 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission Confidential treatment has been requested with respect to portions of t |
|
| September 8, 2015 |
EX-4.1 3 d71255dex41.htm EX-4.1 Exhibit 4.1 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS (this “Agreement”) is dated as of this 20th day of August, 2015, by and among (i) Raptor Pharmaceutical Corp., a Delaware corporation, and any successor corporation (the “Company”), (ii) Tripex Pharmaceuticals, LLC, a Delaware limited liability company (“Tripex”), and (iii) the pers |
|
| August 21, 2015 |
EX-99.1 Exhibit 99.1 Raptor Pharmaceutical Corp. Expands Rare Disease Portfolio with the Acquisition of QuinsairTM First Inhaled Fluoroquinolone Therapy for Patients with Cystic Fibrosis Approval Received in the European Union and Canada Expansion of Pipeline with Multiple Late-Stage Orphan Indication Opportunities Raptor to Host Conference Call and Webcast Today at 5:30 p.m. EDT/2:30 p.m. PDT NOV |
|
| August 21, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Commis |
|
| August 6, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Commiss |
|
| August 6, 2015 |
Exhibit 99.1 Raptor Pharmaceutical Corp. Reports Second Quarter 2015 Financial Results and Provides Corporate Update PROCYSBI ? Product Sales Increased 43% Year over Year to $23.3 Million in Second Quarter Balance Sheet Strengthened with over $220 Million in Cash, Cash Equivalents and Short-Term Investments as of June 30, 2015 Company to Host Conference Call and Webcast Today at 4:30 p.m. ET/1:30 |
|
| August 6, 2015 |
10-Q 1 form10q.htm RAPTOR PHARMACEUTICAL CORP 10-Q 6-30-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000- |
|
| July 22, 2015 |
U.S. Securities and Exchange Commission July 22, 2015 Page 1 July 22, 2015 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jim B. Rosenberg, Senior Assistant Chief Accountant Re: Raptor Pharmaceutical Corp. Form 10-K for the Fiscal Year Ended December 31, 2014 Filed March 2, 2015 Form 10-Q for the Quarterly Period Ended M |
|
| July 17, 2015 |
TRANSITION AND SEPARATION AGREEMENT EX-10.1 Exhibit 10.1 TRANSITION AND SEPARATION AGREEMENT This Transition and Separation Agreement (the ?Agreement?) is made by and between Thomas E. Daley (?Executive?) and Raptor Pharmaceutical Corp., a Delaware corporation (the ?Company?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?), effective eight (8) days after Executive?s signature hereto (the ?Effecti |
|
| July 17, 2015 |
Raptor Pharmaceutical FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) |
|
| July 17, 2015 |
Unassociated Document POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of (i) Corporate Counsel of Raptor Pharmaceuticals Corp. |
|
| June 9, 2015 |
Raptor Pharmaceutical RAPTOR PHARMACEUTICAL CORP S-8 6-9-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RAPTOR PHARMACEUTICAL CORP. (Exact Name of Registrant as Specified in Its Charter) Delaware 86-0883978 (State of Incorporation) (I.R.S. Employer Identification No.) 7 Hamilton Landing, Suite 100 Novato, CA 94949 (Address of Principal Executive Offices including Z |
|
| May 20, 2015 |
Raptor Pharmaceutical RAPTOR PHARMACEUTICAL CORP 8-K 5-19-2015 (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Commissio |
|
| May 18, 2015 |
Raptor Pharmaceutical RAPTOR PHARMACEUTICAL CORP DEFA 14A 5-18-2015 DEFA14A 1 formdefa14a.htm RAPTOR PHARMACEUTICAL CORP DEFA 14A 5-18-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant T Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| May 18, 2015 |
AMENDED AND RESTATED RAPTOR PHARMACEUTICAL CORP. TABLE OF CONTENTS Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF RAPTOR PHARMACEUTICAL CORP. TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS? MEETINGS 1 Section 4. Place Of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 3 Section 7. Notice Of Meetings 3 Section 8. Qu |
|
| May 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Commissio |
|
| May 18, 2015 |
CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF RAPTOR PHARMACEUTICAL CORP. EX-3.1 2 ex31.htm EXHIBIT 3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF RAPTOR PHARMACEUTICAL CORP. The undersigned, being the duly elected and acting Secretary of Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), does hereby certify that on May 18, 2015, the Board of Directors of the Company duly approved an amendment to the Amended and Restated |
|
| May 7, 2015 |
RAPTOR PHARMACEUTICAL CORP. 2010 STOCK INCENTIVE PLAN 2015 RESTRICTED SHARE UNIT AWARD AGREEMENT Exhibit 10.3 RAPTOR PHARMACEUTICAL CORP. 2010 STOCK INCENTIVE PLAN 2015 RESTRICTED SHARE UNIT AWARD AGREEMENT Raptor Pharmaceutical Corp., a Delaware corporation, (the ?Company?), pursuant to its 2010 Stock Incentive Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (the ?Participant?), an award of restricted share units (?Restricted Share Units? or ?RSUs?). |
|
| May 7, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Commission |
|
| May 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-25571 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant |
|
| May 7, 2015 |
Exhibit 99.1 Raptor Pharmaceutical Reports First Quarter 2015 Financial Results and Provides Corporate Update Reports PROCYSBI ? Sales of $20.5 Million in First Quarter Company to Host Conference Call and Webcast Today at 4:30 p.m. ET/1:30 p.m. PT NOVATO, Calif., May 7, 2015 - Raptor Pharmaceutical Corp. (NASDAQ: RPTP) reported financial results for the first quarter ended March 31, 2015 and provi |
|
| May 5, 2015 |
Raptor Pharmaceutical RAPTOR PHARMACEUTICAL CORP DEFA 14A 5-5-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant T Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2)) ? Definitive Proxy Statem |
|
| April 15, 2015 |
AWARENESS LETTER FROM GRANT THORNTON LLP Exhibit 15.1 AWARENESS LETTER FROM GRANT THORNTON LLP Raptor Pharmaceutical Corp. 7 Hamilton Landing, Suite 100 Novato, CA 94949 We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited interim condensed consolidated financial information of Raptor Pharmaceutical Corp. for the three-month period ended March 31, 2013, the thr |
|
| April 15, 2015 |
Raptor Pharmaceutical RAPTOR PHARMACEUTICAL CORP POS AM 4-15-2015 As filed with the Securities and Exchange Commission on April 15, 2015 Registration No. |
|
| April 8, 2015 |
EXHIBIT A Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common stock, par value $0. |
|
| April 8, 2015 |
RPTP / Raptor Pharmaceutical Corp. / Ivanishvili Bidzina Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 Raptor Pharmaceutical Corporation (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 75382F106 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| April 3, 2015 |
Raptor Pharmaceutical Corp. 9,500,000 Shares Common Stock ($0.001 par value) Underwriting Agreement EX-1.1 Exhibit 1.1 EXECUTION VERSION Raptor Pharmaceutical Corp. 9,500,000 Shares Common Stock ($0.001 par value) Underwriting Agreement New York, New York April 1, 2015 To the Representatives named in Schedule I hereto of the several Underwriters named in Schedule II hereto Ladies and Gentlemen: Raptor Pharmaceutical Corp., a corporation organized under the laws of Delaware (the Company), propo |
|
| April 3, 2015 |
Raptor Pharmaceutical FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) |
|
| April 2, 2015 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-203095 CALCULATION OF REGISTRATION FEE Title of Securities Being Registered Amount to be Registered Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, par value $0.001 per share 10,925,000(2) $9.00 $98,325,000 $11,426 (1) Calculated in accordanc |
|
| March 30, 2015 |
SUBJECT TO COMPLETION, DATED MARCH 30, 2015 424B5 1 d899488d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-203095 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus is |
|
| March 30, 2015 |
STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (in thousands, except ratios) EX-21.1 Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (in thousands, except ratios) The following table sets forth our deficiency of earnings to fixed charges for the years ended December 31, 2014 and 2013, the four month period ended December 31, 2012 and the fiscal years ended August 31, 2012, 2011 and 2010. As the ratios of earnings to fixed charges indicate |
|
| March 30, 2015 |
S-3ASR As filed with the Securities and Exchange Commission on March 30, 2015 Registration No. |
|
| March 26, 2015 |
CORRESP Raptor Pharmaceutical Corp. 7 Hamilton Landing, Suite 100 Novato, California 94949 March 26, 2015 VIA EDGAR TRANSMISSION Jeffrey P. Riedler, Assistant Director Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Raptor Pharmaceutical Corp. Post-Effective Amendment No. 2 to Registration Statement on Form S-3 Filed March 2, 20 |
|
| March 26, 2015 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2)) ☒ Defin |
|
| March 26, 2015 |
Raptor Pharmaceutical RAPTOR PHARMACEUTICAL CORP DEFA14A 3-26-2015 DEFA14A 1 formdefa14a.htm RAPTOR PHARMACEUTICAL CORP DEFA14A 3-26-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use |
|
| March 6, 2015 |
Raptor Pharmaceutical RAPTOR PHARMACEUTICAL CORP S-8 3-6-2015 As filed with the Securities and Exchange Commission on March 6, 2015 Registration No. |
|
| March 2, 2015 |
STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (in thousands) Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (in thousands) The following table sets forth our deficiency of earnings to fixed charges for the year ended December 31, 2013, the four month period ended December 31, 2012, the fiscal years ended August 31, 2012, 2011, 2010, 2009, and the nine months ended September 30, 2014. As the ratios of earnings to fixed cha |
|
| March 2, 2015 |
Exhibit 21.1 LIST OF SUBSIDIARIES NAME OF SUBSIDIARY JURISDICTION OF INCORPORATION Raptor Pharmaceuticals Inc. (formerly known as Raptor Therapeutics Inc.), wholly-owned subsidiary of Registrant Delaware, United States Raptor European Products, LLC, wholly-owned subsidiary of Raptor Pharmaceuticals Inc. Delaware, United States, business office in Grand Cayman RPTP European Holdings C.V., wholly-ow |
|
| March 2, 2015 |
Exhibit 10.50 FOURTH AMENDMENT to LICENSE AGREEMENT UC CONTROL NUMBER 2008-03-0236, EFFECTIVE OCTOBER 31, 2007 between RAPTOR PHARMACEUTICALS, INC. and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA for: CASE NO. SD2006-092: ?Enterically Coated Cysteamine? This fourth amendment (?Fourth Amendment?) to the License Agreement, UC Control No. 2008-03-0236, for Case No. SD2006-092 ?Enterically Coated Cyst |
|
| March 2, 2015 |
RAPTOR PHARMACEUTICAL CORP. 2014 EMPLOYMENT COMMENCEMENT STOCK INCENTIVE PLAN Award Agreement Exhibit 10.46 RAPTOR PHARMACEUTICAL CORP. 2014 EMPLOYMENT COMMENCEMENT STOCK INCENTIVE PLAN Award Agreement In consideration of your commencement of employment with the Company and for other good and valuable consideration, effective as of the Grant Date set forth below, you are hereby awarded this stock option (“Option”) (in electronic format) to purchase Shares of Raptor Pharmaceutical Corp. (th |
|
| March 2, 2015 |
STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (in thousands) Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (in thousands) The following table sets forth our deficiency of earnings to fixed charges for the years ended December 31, 2014 and 2013, the four-month period ended December 31, 2012 and the fiscal years ended August 31, 2012, 2011 and 2010. As the ratios of earnings to fixed charges indicate less than one-to-one c |
|
| March 2, 2015 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.47 EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the ?Agreement?) is entered into as of October 13, 2014, by and between David Happel (?Executive?) and Raptor Pharmaceutical Corp. (the ?Company?). Whereas, the Company desires to employ Executive as its Chief Commercial Officer effective as of October 13, 2014 (the ?Effective Date?), and Executi |
|
| March 2, 2015 |
Exhibit 10.49 THIRD AMENDMENT to LICENSE AGREEMENT UC CONTROL NUMBER 2008-03-0236, EFFECTIVE OCTOBER 31, 2007 between RAPTOR THERAPEUTICS, INC. and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA for: CASE NO. SD2006-092: “Enterically Coated Cysteamine” This third amendment (“Third Amendment”) to the License Agreement, UC Control No. 2008-03-0236, for Case No. SD2006-092 “Enterically Coated Cysteamine |
|
| March 2, 2015 |
RAPTOR PHARMACEUTICAL CORP. 2014 EMPLOYMENT COMMENCEMENT STOCK INCENTIVE PLAN Plan Document Exhibit 10.45 RAPTOR PHARMACEUTICAL CORP. 2014 EMPLOYMENT COMMENCEMENT STOCK INCENTIVE PLAN ———————————————— Plan Document ———————————————— 1. Introduction. (a) Purpose. Raptor Pharmaceutical Corp. (the “Company”) hereby establishes this equity-based incentive compensation plan to be known as the Raptor Pharmaceutical Corp. 2014 Employment Commencement Stock Incentive Plan (the “Plan”), for the fo |
|
| March 2, 2015 |
AWARENESS LETTER FROM GRANT THORNTON LLP Exhibit 15.1 AWARENESS LETTER FROM GRANT THORNTON LLP Raptor Pharmaceutical Corp. 7 Hamilton Landing, Suite 100 Novato, CA 94949 We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited interim condensed consolidated financial information of Raptor Pharmaceutical Corp. for the three-month period ended March 31, 2013, the thr |
|
| March 2, 2015 |
10-K 1 form10k.htm RAPTOR PHARMACEUTICAL, CORP 10-K 12-31-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
|
| March 2, 2015 |
RPTP / Raptor Pharmaceutical Corp. POS AM - - RAPTOR PHARMACEUTICALS CORP POS AM 3-2-2015 As filed with the Securities and Exchange Commission on March 2, 2015 Registration No. |
|
| March 2, 2015 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.48 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is entered into as of January 2, 2015, by and between Krishna Polu, M.D. (?Executive?) and Raptor Pharmaceutical Corp. (the ?Company?). Whereas, the Company desires to employ Executive as its Chief Medical Officer effective as of January 12, 2015 (the ?Effective Date?), and Executive desires to serve |
|
| March 2, 2015 |
RPTP / Raptor Pharmaceutical Corp. POSASR - - RAPTOR PHARMACEUTICAL CORP POS ASR 3-2-2015 As filed with the Securities and Exchange Commission on March 2, 2015 Registration No. |
|
| March 2, 2015 |
AWARENESS LETTER FROM GRANT THORNTON LLP Exhibit 15.1 AWARENESS LETTER FROM GRANT THORNTON LLP Raptor Pharmaceutical Corp. 7 Hamilton Landing, Suite 100 Novato, CA 94949 We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited interim condensed consolidated financial information of Raptor Pharmaceutical Corp. for the three-month period ended March 31, 2013, the thr |
|
| February 26, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Comm |
|
| February 26, 2015 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Raptor Pharmaceutical Reports Fourth Quarter and Full Year 2014 Financial Results and Provides 2015 Corporate Update Global Net Product Sales for PROCYSBI® of $69.5 Million for 2014 2015 PROCYSBI Revenue Guidance of $80-$90 Million Company to Host Conference Call and Webcast Today at 4:30 p.m. ET/1:30 p.m. PT NOVATO, Calif., February 26, 2015 - Raptor |
|
| February 17, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* raptor pharmaceutical corp. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 75382F106 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 13, 2015 |
Other Events, Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Comm |
|
| February 6, 2015 |
RPTP / Raptor Pharmaceutical Corp. / CREDIT SUISSE - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Raptor Pharmaceutical Corp. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 75382F106 (CUSIP Number) Calendar Year 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 6, 2015 |
EX-99.1 2 csraptor13ga1ex991.htm EX-99.1 Exhibit 99.1 In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they constitute the Private Banking and Wealth Management Division other than the Alternative Investments business (the "AI |
|
| January 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2015 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Commis |
|
| January 7, 2015 |
Exhibit 99.1 Raptor Pharmaceutical Appoints Krishna Polu, M.D. as Chief Medical Officer and Michael Smith as Chief Financial Officer NOVATO, Calif., January 7, 2015 - Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced the appointment of Krishna R. Polu, M.D., as its Chief Medical Officer and Michael P. Smith as Chief Financial Officer, effective January 12, 2015. Dr. Polu will oversee all |
|
| January 7, 2015 |
EXECUTIVE EMPLOYMENT AGREEMENT EX-10.1 2 ex101.htm EXHIBIT 10.1 Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of January 2, 2015, by and between Michael Smith (“Executive”) and Raptor Pharmaceutical Corp. (the “Company”). Whereas, the Company desires to employ Executive as its Chief Financial Officer effective as of January 12, 2015 (the “Effective Date”), a |
|
| December 18, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2014 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Comm |
|
| December 18, 2014 |
Raptor Pharmaceutical Appoints Gregg Lapointe and Georges Gemayel to Board of Directors Exhibit 99.1 Raptor Pharmaceutical Appoints Gregg Lapointe and Georges Gemayel to Board of Directors NOVATO, Calif., December 18, 2014 - Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced the appointment of Gregg Lapointe and Georges Gemayel, Ph.D. to its Board of Directors, effective January 1, 2015. As previously disclosed, they will be joining Julie Anne Smith, President and CEO-Designa |
|
| December 5, 2014 |
Exhibit 99.1 In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they constitute the Private Banking and Wealth Management Division other than the Alternative Investments business (the "AI Business") and U.S. private client servic |
|
| December 5, 2014 |
RPTP / Raptor Pharmaceutical Corp. / CREDIT SUISSE - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Raptor Pharmaceutical Corp. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 75382F106 (CUSIP Number) July 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 6, 2014 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Raptor Pharmaceutical Reports Third Quarter 2014 Financial Results and Provides Corporate Update Global Net Product Sales for PROCYSBI® of $23.8 Million for Third Quarter 2014 PROCYSBI Revenue of $52.2 Million Reached Through September 2014 PROCYSBI Revenue Guidance of $65-$70 Million Maintained 2014 Cash Operating Expense Guidance Narrowed to $80-$85 |
|
| November 6, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2014 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-25571 (Commission File |
|
| November 6, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-25571 RAPTOR PHARMACEUTICAL CORP. (Exact name of registr |
|
| October 24, 2014 |
Raptor Pharmaceutical Announces Management Changes EX-99.1 3 d808092dex991.htm EX-99.1 Exhibit 99.1 Raptor Pharmaceutical Announces Management Changes NOVATO, Calif., October 23, 2014 — Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced that it has strengthened its leadership team with the hiring of two new executives: David Happel, Chief Commercial Officer, who will oversee Raptor’s global commercial operations, and Kimberly Lee, D.O., Vi |
|
| October 24, 2014 |
SEPARATION AGREEMENT AND GENERAL RELEASE EX-10.1 2 d808092dex101.htm EX-10.1 Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (“Agreement”) is made by and between Georgia Erbez (“Executive”) and Raptor Pharmaceutical Corporation (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”), effective as of the eighth day following Executive’s signat |
|
| October 24, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2014 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporatio |
|
| October 3, 2014 |
RPTP / Raptor Pharmaceutical Corp. / Hyperion Trading Segregated Portfolio Passive Investment SC 13G/A 1 raptor13gam6aug2014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* RAPTOR PHARMACEUTICAL CORP. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 75382F106 (CUSIP Number) January 1, 2013 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| October 3, 2014 |
RPTP / Raptor Pharmaceutical Corp. / Hyperion Trading Segregated Portfolio Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* RAPTOR PHARMACEUTICAL CORP. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 75382F106 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| October 3, 2014 |
RPTP / Raptor Pharmaceutical Corp. / Hyperion Trading Segregated Portfolio Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RAPTOR PHARMACEUTICAL CORP. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 75382F106 (CUSIP Number) August 12, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| October 3, 2014 |
RPTP / Raptor Pharmaceutical Corp. / Hyperion Trading Segregated Portfolio Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* RAPTOR PHARMACEUTICAL CORP. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 75382F106 (CUSIP Number) December 20, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| October 3, 2014 |
RPTP / Raptor Pharmaceutical Corp. / Hyperion Trading Segregated Portfolio Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* RAPTOR PHARMACEUTICAL CORP. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 75382F106 (CUSIP Number) May 3, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| October 3, 2014 |
RPTP / Raptor Pharmaceutical Corp. / Hyperion Trading Segregated Portfolio Passive Investment SC 13G/A 1 raptor13gam5aug2014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* RAPTOR PHARMACEUTICAL CORP. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 75382F106 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| October 3, 2014 |
RPTP / Raptor Pharmaceutical Corp. / Hyperion Trading Segregated Portfolio Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* RAPTOR PHARMACEUTICAL CORP. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 75382F106 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| October 3, 2014 |
RPTP / Raptor Pharmaceutical Corp. / Hyperion Trading Segregated Portfolio Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* RAPTOR PHARMACEUTICAL CORP. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 75382F106 (CUSIP Number) March 28, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| September 5, 2014 |
RPTP / Raptor Pharmaceutical Corp. S-3ASR - - RAPTOR PHARMACEUTICAL CORP S-3 ASR 9-5-2014 S-3ASR 1 forms3asr.htm RAPTOR PHARMACEUTICAL CORP S-3 ASR 9-5-2014 As filed with the Securities and Exchange Commission on September 5, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT Under The Securities Act of 1933 Raptor Pharmaceutical Corp. (Exact name of Registrant as specified in its charter) Delaware 86-08839 |
|
| August 21, 2014 |
RAPTOR PHARMACEUTICAL CORP. SECOND AMENDED AND RESTATED SALES AGREEMENT EX-10.1 EXHIBIT 10.1 RAPTOR PHARMACEUTICAL CORP. $100,000,000 SECOND AMENDED AND RESTATED SALES AGREEMENT August 21, 2014 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. |
|
| August 21, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2014 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Co |
|
| August 21, 2014 |
EX-10.1 Exhibit 10.1 Execution Version U.S. $60,000,000 AMENDED AND RESTATED LOAN AGREEMENT Amended and Restated as of July 1, 2014 among HEALTHCARE ROYALTY PARTNERS II, L.P., as Lender, RAPTOR PHARMACEUTICAL CORP., as Borrower and the Guarantors from time to time party hereto, as Guarantors [*****] Certain information in this document has been omitted and filed separately with the Securities and |
|
| August 21, 2014 |
Filed Pursuant to Rule 424(b)(5) Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| August 21, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2014 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) ( |
|
| August 15, 2014 |
RPTP / Raptor Pharmaceutical Corp. S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on August 15, 2014 Registration No. |
|
| August 7, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2014 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-25571 (Commission File Nu |
|
| August 7, 2014 |
Exhibit 99.1 Raptor Pharmaceutical Reports Second Quarter 2014 Financial Results and Provides Corporate Update Global net product sales for PROCYSBI® of $16.3 million reported for second quarter 2014 Raising net sales guidance for PROCYSBI to $65 to $70 million for 2014 Company to host conference call and webcast today at 4:30 p.m. EDT NOVATO, Calif., August 7, 2014 - Raptor Pharmaceutical Corp. ( |
|
| August 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-25571 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant a |
|
| August 5, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2014 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-25571 (Commission File Nu |
|
| August 5, 2014 |
Exhibit 99.1 Raptor Receives Orphan Drug Designation for Cysteamine Bitartrate in Huntington's Disease from the European Commission Orphan designation provides 10 years of EU market exclusivity upon approval NOVATO, Calif., August 4, 2014 - Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced that the European Commission (EC) approved its application for orphan drug designation of cysteamine |
|
| August 4, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2014 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Commissi |
|
| July 29, 2014 |
RPTP / Raptor Pharmaceutical Corp. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary proxy statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive pro |
|
| July 29, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2014 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) (Comm |
|
| July 21, 2014 |
RPTP / Raptor Pharmaceutical Corp. DEFA14A - - DEFINITIVE ADDITIONAL MATERIALS Definitive additional materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 11, 2014 |
SC 13G 1 sc13g.htm RAPTOR PHARMACEUTICAL CORP. (AS ISSUER) SCHEDULE 13G DATED JULY 1, 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Raptor Pharmaceutical Corp. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 75382F106 (CUSIP Number) July 1, 2014 (Date of Event Which Requir |
|
| July 8, 2014 |
TRANSITION AND SEPARATION AGREEMENT EX-10.2 Exhibit 10.2 TRANSITION AND SEPARATION AGREEMENT This Transition and Separation Agreement (the “Agreement”) by and between Christopher M. Starr, Ph.D. (“Executive”) and Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), is made effective as of the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts: A. Executive’s employment wi |
|
| July 8, 2014 |
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT EX-10.1 Exhibit 10.1 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of July 7, 2014 (the “Effective Date”), by and between Julie Anne Smith (“Executive”) and Raptor Pharmaceutical Corp. (the “Company”). WHEREAS, the Company and Executive entered into that certain Employment Agreement entered into as |
|
| July 8, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2014 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 000-25571 86-0883978 (State or other jurisdiction of incorporation) ( |
|
| July 8, 2014 |
EX-99.1 Exhibit 99.1 Raptor Announces CEO Succession Plan; Dr. Christopher Starr to retire as CEO at Year-end 2014, Julie Anne Smith Named President and CEO-Designate Novato, California - July 7, 2014 - Raptor Pharmaceuticals (NASDAQ: RPTP) today announced that Julie Anne Smith, Executive Vice President, Strategy and Chief Operating Officer at Raptor, has been named President and CEO-designate eff |
|
| July 3, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2014 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-25571 (Commission File Numb |
|
| July 3, 2014 |
RAPTOR PHARMACEUTICAL CORP., as Issuer, HEALTHCARE ROYALTY PARTNERS II, L.P., HCRP OVERFLOW FUND, L.P. AND MOLAG HEALTHCARE ROYALTY, LLC, each as Holder AND the Guarantors from time to time party hereto, as Guarantors Convertible Note Purchase Agreement Dated as of July 1, 2014 8.0% Convertible Senior Notes due 2019 TABLE OF CONTENTS Page ARTICLE 1. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPL |
|
| July 3, 2014 |
Exhibit 99.1 Raptor Pharmaceutical Enters into $70 Million Financing Transaction and Amended Loan Agreement with HealthCare Royalty Partners – Financing includes $60 million 8% notes convertible at $17.50 per share, and $10 million additional funding pursuant to a revised Synthetic Royalty® Loan Agreement - NOVATO, Calif., July 1, 2014 – Raptor Pharmaceutical Corp. (NASDAQ: RPTP) today announced t |
|
| June 18, 2014 |
- PROXY NOTICE AND ACCESS 2014 ANNUAL MEETING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive |
|
| June 17, 2014 |
- RAPTOR PROXY 2014 ANNUAL MEETING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2)) [X] Definitive Proxy St |
|
| June 2, 2014 |
RPTP / Raptor Pharmaceutical Corp. / Ivanishvili Bidzina Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Raptor Pharmaceutical Corporation (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 75382F106 (CUSIP Number) March 25, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| May 12, 2014 |
STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (in thousands) Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (in thousands) The following table sets forth our deficiency of earnings to fixed charges for the year ended December 31, 2013, the four month period ended December 31, 2012, the fiscal years ended August 31, 2012, 2011, 2010, 2009, and the three months ended March 31, 2014. As the ratios of earnings to fixed charge |
|
| May 12, 2014 |
10-Q/A 1 form10qa.htm RAPTOR PHARMACEUTICALS CORP 10-Q A 3-31-2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 2) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 F |
|
| May 12, 2014 |
10-Q/A 1 form10qa.htm RAPTOR PHARMACEUTICAL CORP. 10-Q A 6-30-2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Fo |
|
| May 12, 2014 |
- RAPTOR PHARMACEUTICALS CORP 10-KT A NO 2 12-31-2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) o ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended x TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from September 1, 2012 to December 31, 2012 Commission file number 0 |
|
| May 12, 2014 |
10-Q/A 1 form10qa.htm RAPTOR PHARMACEUTICAL CORP. 10-Q/A 9-30-2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 |
|
| May 12, 2014 |
AWARENESS LETTER FROM GRANT THORNTON LLP EXHIBIT 15.1 AWARENESS LETTER FROM GRANT THORNTON LLP Raptor Pharmaceutical Corp. 5 Hamilton Landing, Suite 160 Novato, CA 94949 We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited condensed consolidated interim financial information of Raptor Pharmaceutical Corp. and subsidiaries as of September 30, 2013 and for the th |
|
| May 12, 2014 |
AWARENESS LETTER FROM GRANT THORNTON LLP Exhibit 15.1 AWARENESS LETTER FROM GRANT THORNTON LLP Raptor Pharmaceutical Corp. 5 Hamilton Landing, Suite 160 Novato, CA 94949 We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited interim condensed consolidated financial information of Raptor Pharmaceutical Corp. for the three-month period ended March 31, 2013, the thr |
|
| May 12, 2014 |
AWARENESS LETTER FROM GRANT THORNTON LLP Exhibit 15.1 AWARENESS LETTER FROM GRANT THORNTON LLP Raptor Pharmaceutical Corp. 5 Hamilton Landing, Suite 160 Novato, CA 94949 We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited condensed consolidated interim financial information of Raptor Pharmaceutical Corp. and subsidiaries as of June 30, 2013 and for the three a |
|
| May 12, 2014 |
- RAPTOR PHARMACEUTICAL CORP. S-3 ASR 5-12-2014 As filed with the Securities and Exchange Commission on May 12, 2014 Registration No. |
|
| May 12, 2014 |
AWARENESS LETTER FROM GRANT THORNTON LLP Exhibit 15.1 AWARENESS LETTER FROM GRANT THORNTON LLP Raptor Pharmaceutical Corp. 5 Hamilton Landing, Suite 160 Novato, CA 94949 We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited condensed consolidated interim financial information of Raptor Pharmaceutical Corp. and subsidiaries as of March 31, 2013 and for the three |
|
| May 9, 2014 |
- RAPTOR PHARMACEUTICALS CORP 8-A12B/A 5-9-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A Amendment No. 1 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware 86-0883978 (State of incorporation or organization) (I.R.S. Employer Identification N |
|
| May 9, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-25571 Raptor Pharmaceutical Corp. (Exact name of registrant |
|
| May 8, 2014 |
Exhibit 99.1 Raptor Pharmaceutical Reports First Quarter 2014 Financial Results and Provides Corporate Update Reports PROCYSBI® net product sales of $12.1 million in first quarter 2014 and launch of PROCYSBI® in Germany Company to host conference call and webcast today at 4:30 p.m. EDT NOVATO, Calif., May 8, 2014 - Raptor Pharmaceutical Corp. (NASDAQ: RPTP) today reported financial results for the |
|
| May 8, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2014 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-25571 (Commission File Numbe |
|
| March 17, 2014 |
Exhibit 21.1 LIST OF SUBSIDIARIES NAME OF SUBSIDIARY JURISDICTION OF INCORPORATION Raptor Pharmaceuticals Inc. (formerly known as Raptor Therapeutics Inc.), wholly-owned subsidiary of Registrant Delaware, United States Raptor European Products, LLC, wholly-owned subsidiary of Raptor Pharmaceuticals Inc. Delaware, United States, business office in Grand Cayman RPTP European Holdings C.V., wholly-ow |
|
| March 17, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-50720 Raptor |
|
| March 13, 2014 |
EX-99.1 2 rptp031314fye123113prrls.htm RAPTOR PHARMACEUTICAL PRESS RELEASE DATED MARCH 13, 2013 Exhibit 99.1 Raptor Pharmaceutical Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Corporate Update 2014 guidance of $55-$65 million of net sales for PROCYSBI® Company to host conference call and webcast today at 4:30 p.m. EDT NOVATO, Calif., March 13, 2014 - Raptor Pharmaceutic |
|
| March 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2014 RAPTOR PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-25571 (Commission File Nu |
|
| February 26, 2014 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF RAPTOR PHARMACEUTICAL CORP. TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place Of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 3 Section 7. Notice Of Meetings 3 Section 8. Qu |
